TVARDI THERAPEUTICS INC (TVRD) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:TVRD • US1407553072

3.72 USD
-0.06 (-1.59%)
Last: Feb 11, 2026, 10:05 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Overall TVRD gets a fundamental rating of 2 out of 10. We evaluated TVRD against 191 industry peers in the Pharmaceuticals industry. TVRD scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TVRD is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • TVRD had negative earnings in the past year.
  • TVRD had a negative operating cash flow in the past year.
  • TVRD had negative earnings in 4 of the past 5 years.
  • TVRD had a negative operating cash flow in each of the past 5 years.
TVRD Yearly Net Income VS EBIT VS OCF VS FCFTVRD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -97.82%, TVRD is doing worse than 77.49% of the companies in the same industry.
Industry RankSector Rank
ROA -97.82%
ROE N/A
ROIC N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TVRD Yearly ROA, ROE, ROICTVRD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

  • With an excellent Gross Margin value of 129.95%, TVRD belongs to the best of the industry, outperforming 98.95% of the companies in the same industry.
  • TVRD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 129.95%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TVRD Yearly Profit, Operating, Gross MarginsTVRD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10K -20K -30K -40K -50K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • TVRD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, TVRD has more shares outstanding
  • The number of shares outstanding for TVRD has been increased compared to 5 years ago.
  • There is no outstanding debt for TVRD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
TVRD Yearly Shares OutstandingTVRD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500K 1M 1.5M
TVRD Yearly Total Debt VS Total AssetsTVRD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • Based on the Altman-Z score of -27.50, we must say that TVRD is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -27.50, TVRD is not doing good in the industry: 86.91% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -27.5
ROIC/WACCN/A
WACC9.46%
TVRD Yearly LT Debt VS Equity VS FCFTVRD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • TVRD has a Current Ratio of 32.48. This indicates that TVRD is financially healthy and has no problem in meeting its short term obligations.
  • TVRD's Current ratio of 32.48 is amongst the best of the industry. TVRD outperforms 95.81% of its industry peers.
  • A Quick Ratio of 31.73 indicates that TVRD has no problem at all paying its short term obligations.
  • TVRD has a Quick ratio of 31.73. This is amongst the best in the industry. TVRD outperforms 95.81% of its industry peers.
Industry RankSector Rank
Current Ratio 32.48
Quick Ratio 31.73
TVRD Yearly Current Assets VS Current LiabilitesTVRD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. Growth

3.1 Past

  • The earnings per share for TVRD have decreased strongly by -37.11% in the last year.
  • TVRD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -49.96%.
  • The Revenue has been growing by 9.21% on average over the past years. This is quite good.
EPS 1Y (TTM)-37.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.87%
Revenue 1Y (TTM)-49.96%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-100%

3.2 Future

  • TVRD is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.42% yearly.
  • Based on estimates for the next years, TVRD will show a very negative growth in Revenue. The Revenue will decrease by -14.87% on average per year.
EPS Next Y98.33%
EPS Next 2Y40.29%
EPS Next 3Y25.43%
EPS Next 5Y14.42%
Revenue Next Year-82.49%
Revenue Next 2Y-89.11%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
TVRD Yearly Revenue VS EstimatesTVRD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2029 2030 2031 2032 2033 20M 40M 60M 80M 100M
TVRD Yearly EPS VS EstimatesTVRD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -20 -40 -60 -80

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for TVRD. In the last year negative earnings were reported.
  • Also next year TVRD is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TVRD Price Earnings VS Forward Price EarningsTVRD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TVRD Per share dataTVRD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

  • A more expensive valuation may be justified as TVRD's earnings are expected to grow with 25.43% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.29%
EPS Next 3Y25.43%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TVRD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TVARDI THERAPEUTICS INC

NASDAQ:TVRD (2/11/2026, 10:05:22 AM)

3.72

-0.06 (-1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-13
Earnings (Next)03-09
Inst Owners28.19%
Inst Owner Change2.81%
Ins Owners17.49%
Ins Owner Change0%
Market Cap34.89M
Revenue(TTM)20.97M
Net Income(TTM)-38.10M
Analysts77.14
Price Target15.15 (307.26%)
Short Float %9.24%
Short Ratio4.94
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)49.63%
Min Revenue beat(2)-10.63%
Max Revenue beat(2)109.89%
Revenue beat(4)2
Avg Revenue beat(4)34.26%
Min Revenue beat(4)-17.21%
Max Revenue beat(4)109.89%
Revenue beat(8)4
Avg Revenue beat(8)5.44%
Revenue beat(12)7
Avg Revenue beat(12)0.17%
Revenue beat(16)9
Avg Revenue beat(16)-1.11%
PT rev (1m)0%
PT rev (3m)-24.64%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)26.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.96
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-78.48
EYN/A
EPS(NY)-2.5
Fwd EYN/A
FCF(TTM)-3.82
FCFYN/A
OCF(TTM)-3.8
OCFYN/A
SpS0.53
BVpS-0.86
TBVpS-0.86
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -97.82%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 129.95%
FCFM N/A
ROA(3y)-100.93%
ROA(5y)-67.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 32.48
Quick Ratio 31.73
Altman-Z -27.5
F-Score5
WACC9.46%
ROIC/WACCN/A
Cap/Depr(3y)492.59%
Cap/Depr(5y)332.09%
Cap/Sales(3y)8.69%
Cap/Sales(5y)5.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-37.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.87%
EPS Next Y98.33%
EPS Next 2Y40.29%
EPS Next 3Y25.43%
EPS Next 5Y14.42%
Revenue 1Y (TTM)-49.96%
Revenue growth 3Y-46.26%
Revenue growth 5Y9.21%
Sales Q2Q%-100%
Revenue Next Year-82.49%
Revenue Next 2Y-89.11%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y81.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year68.07%
EBIT Next 3Y12.96%
EBIT Next 5YN/A
FCF growth 1Y59.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y59.45%
OCF growth 3YN/A
OCF growth 5YN/A

TVARDI THERAPEUTICS INC / TVRD FAQ

What is the fundamental rating for TVRD stock?

ChartMill assigns a fundamental rating of 2 / 10 to TVRD.


What is the valuation status of TVARDI THERAPEUTICS INC (TVRD) stock?

ChartMill assigns a valuation rating of 1 / 10 to TVARDI THERAPEUTICS INC (TVRD). This can be considered as Overvalued.


What is the profitability of TVRD stock?

TVARDI THERAPEUTICS INC (TVRD) has a profitability rating of 1 / 10.


What is the expected EPS growth for TVARDI THERAPEUTICS INC (TVRD) stock?

The Earnings per Share (EPS) of TVARDI THERAPEUTICS INC (TVRD) is expected to grow by 98.33% in the next year.